Results 171 to 180 of about 2,392 (196)

PNA-mediated Affibody pretargeting

, 2017
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pretargeting

Cancer, 1997
Human imaging studies show that maximum human tumor concentrations of monoclonal antibody (MoAb) are achieved in 1 day, but several days are required for background reduction and sensitive radioimmunoscintigraphy of tumors. With therapeutic radionuclides such as yttrium-90 (90Y), this long biologic half-life imposes a high radiation burden on sensitive
David A. Goodwin, Claude F. Meares
openaire   +3 more sources

Pretargeting: A Path Forward for Radioimmunotherapy

Journal of Nuclear Medicine, 2022
Pretargeted radioimmunodiagnosis and radioimmunotherapy aim to efficiently combine antitumor antibodies and medicinal radioisotopes for high-contrast imaging and high-therapeutic-index (TI) tumor targeting, respectively. As opposed to conventional radioimmunoconjugates, pretargeted approaches separate the tumor-targeting step from the payload step ...
Sarah M, Cheal, Sebastian K, Chung, Brett A, Vaughn, Nai-Kong V, Cheung, Steven M, Larson   +4 more
openaire   +2 more sources

Advances in pretargeting biotechnology

Biotechnology Advances, 2001
A major focus of current drug research is to improve drug targeting to internal target sites such as to solid tumors or specific organs. The objective of drug targeting, especially for cancer chemotherapy and radioimmunotherapy, is to enhance the effectiveness of the drug by concentrating it at the target site and minimizing its effects in nontarget ...
D A, Goodwin, C F, Meares
openaire   +2 more sources

Recent Advances in Pretargeted Radioimmunotherapy

Current Medicinal Chemistry, 2005
Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity ...
A, Gruaz-Guyon, O, Raguin, J, Barbet
openaire   +2 more sources

Pretargeting using peptide nucleic acid

Cancer, 1997
Pretargeting studies in animals and humans have usually involved (strept)avidin and biotin. Depending on the particular strategy, endogenous biotin can adversely influence localization when these molecules are used.As an alternative to (strept)avidin and biotin, we have explored the use of a single-stranded peptide nucleic acid (PNA) bound to a protein
M, Rusckowski, T, Qu, F, Chang, D J, Hnatowich   +3 more
openaire   +2 more sources

Pretargeted PET of Osteodestructive Lesions in Dogs

Molecular Pharmaceutics, 2022
The last decade has witnessed the creation of a highly effective approach to in vivo pretargeting based on the inverse electron demand Diels-Alder (IEDDA) click ligation between tetrazine (Tz) and trans-cyclooctene (TCO). Despite the steady progression of this technology toward the clinic, concerns have persisted regarding whether this in vivo ...
Charles A. Maitz, Samantha Delaney, Brendon E. Cook, Afaf R. Genady, Rebecca Hoerres, Marina Kuchuk, Georgios Makris, John F. Valliant, Saman Sadeghi, Jason S. Lewis, Heather M. Hennkens, Jeffrey N. Bryan, Brian M. Zeglis   +12 more
openaire   +2 more sources

Doubly radiolabeled liposomes for pretargeted radioimmunotherapy

International Journal of Pharmaceutics, 2007
The aim of this study was to design liposomes as radioactivity carriers for pretargeted radioimmunotherapy with favorable pharmacokinetic parameters. To monitor the liposomes integrity in vivo, their surface was radiolabeled with indium-111 bound to DTPA-derivatized phosphatidylethanolamine (DSPE-DTPA) and the aqueous phase was labeled by using an ...
M, Mougin-Degraef, C, Bourdeau, E, Jestin, C, Saï-Maurel, M, Bourgeois, P Remaud-Le, Saëc, P, Thédrez, J-F, Gestin, J, Barbet, A, Faivre-Chauvet   +9 more
openaire   +2 more sources

Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy

Journal of Clinical Oncology, 2006
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with ...
Goldenberg, David M., Sharkey, Robert M., Paganelli, Giovanni, Barbet, Jacques, Chatal, Jean-François   +4 more
openaire   +3 more sources